THE FUTURE of metabolic-dysfunction associated liver disease (MASLD) was discussed in an insightful session chaired by Hannes Hagström, Karolinska Institutet, Stockholm, Sweden; and Dina Tiniakos, National and Kapodistrian University of Athens, Greece, during the European Association for the Study of the Liver (EASL) Congress 2024, held in Milan, Italy from the 5ᵗʰ–8ᵗʰ June. Hot topics included the evolving role of hepatologists, novel treatments and biomarkers for MASLD, and the promise of AI in the field.
No takes yet. Share an insight, caveat, or question.
Ada Enesco (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: